834
Participants
Start Date
November 30, 2003
Study Completion Date
August 31, 2006
Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
Topiramate - Placebo
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
Innsbruck
Linz
Antwerp
Charleroi
Leuven
Liÿge
Pleven
Plovdiv
Sofia
Hradec nad Svitavou
Prague
Aabenraa
Esbjerg
Glostrup Municipality
Kÿbenhavn K
Odense
Colombes
Lille
Nice
Paris
Rouen
Voiron
Berlin
Essen
München
Mÿnster
Athens
Thessaloniki
Budapest
Budapest Na
Miskolc
Szeged Na
Cork
Dublin
Bodø
Oslo
Trondheim
Gdansk
Krakow Malopolska
Lodz
Mosina Poland
Poznan
Poznan Poland
Warsaw
Coimbra
Lisbon
Porto
Moscow
Saint Petersburg
Riyadh
Ljubljana
Maribor
Madrid
Biel/Bienne
Sankt Gallen
Zurich
Bursa
Istanbul
Brighton
Glasgow
Helensburgh
Leicester
Newcastle upon Tyne
Northampton
Stoke-on-Trent
Sunderland
Surrey
York
Janssen Pharmaceutica N.V., Belgium
INDUSTRY